London, UK – [Insert Date] – The global Alzheimer’s disease (AD) market is on the cusp of a dramatic transformation, with projections indicating a staggering compound annual growth rate (CAGR) of 20.0% from $2.4 billion in 2023 to an impressive $14.7 billion by 2033 across eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China). This substantial expansion, detailed in GlobalData’s latest report, "Alzheimer’s Disease: Eight-Market Drug Forecast and Market Analysis – Update (2026)," is fueled by a confluence of factors including an aging global population, the groundbreaking introduction of expensive disease-modifying therapies (DMTs), and the development of novel symptomatic treatments.
The Shifting Landscape of Alzheimer’s Therapeutics
For decades, the scientific community has intensely focused research and development (R&D) efforts on preventing the accumulation of amyloid-beta (Aβ) plaques, a hallmark pathology of Alzheimer’s disease. While this strategy has been fraught with numerous historical setbacks, recent years have witnessed a significant breakthrough with the emergence of the first DMTs targeting this pathway. The U.S. Food and Drug Administration (FDA) approval of Eisai/Biogen’s Leqembi (lecanemab) in January 2023, followed by Eli Lilly’s Kisunla (donanemab) in July 2024, marked a pivotal moment, offering tangible hope for patients and their families. Both of these groundbreaking therapies have subsequently received approval in the other seven major markets, signaling a global shift towards this new class of treatment.
These approvals represent a monumental stride forward in the fight against Alzheimer’s. However, the journey from laboratory discovery to widespread patient access is complex and multifaceted. A critical hurdle in the integration of these DMTs into routine clinical practice lies in their administration and associated logistical challenges. The current requirement for frequent intravenous (IV) infusions places a considerable burden on healthcare systems and care settings. Furthermore, access to specialized diagnostic imaging, such as positron emission tomography (PET) and magnetic resonance imaging (MRI) scans, is a significant economic and operational barrier that limits broader patient eligibility.
Beyond the logistical considerations, the high cost of these novel DMTs, compared to the largely genericized symptomatic treatments currently in use, presents another formidable access challenge. Reimbursement policies and payer restrictions are proving to be significant gatekeepers. For instance, in Japan, a 15% price reduction for Leqembi was implemented in November 2025 following a cost-effectiveness assessment by the Central Social Insurance Medical Council (Chuikyo). Similarly, across Europe, both Leqembi and Kisunla are encountering reimbursement hurdles due to ongoing cost-benefit analyses.
A Timeline of Progress and Emerging Solutions
The quest for effective Alzheimer’s treatments has been a long and arduous one. However, recent years have seen a surge in progress, culminating in the approval of the first disease-modifying therapies.
- January 2023: The U.S. FDA grants accelerated approval to Leqembi (lecanemab) for the treatment of Alzheimer’s disease.
- July 2024: Eli Lilly’s Kisunla (donanemab) receives FDA approval, offering another new therapeutic option.
- August 2025: The FDA approves Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab, for weekly maintenance dosing in the U.S. This marks a significant step towards at-home administration.
- July 2026: Leqembi Iqlik becomes available for treatment initiation via subcutaneous administration in the U.S., offering the first DMT with the potential for at-home dosing from the outset.
- November 2025: In Japan, Leqembi undergoes a 15% price reduction following a cost-effectiveness assessment.
Recognizing the limitations of IV administration, pharmaceutical developers are actively exploring alternative delivery methods to alleviate the burden on patients and healthcare providers. The U.S. FDA’s approval of Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab, in August 2025 for weekly maintenance dosing, and subsequently for treatment initiation in July 2026, represents a paradigm shift. This innovation positions Leqembi Iqlik as the first DMT offering at-home administration from the commencement of therapy, significantly enhancing patient convenience and potentially improving adherence.
Eli Lilly is also at the forefront of this innovation with its development of remternetug, a second anti-Aβ monoclonal antibody (mAb) designed for subcutaneous administration. Beyond mAbs, a promising pipeline of oral late-stage products with diverse mechanisms of action is emerging. The potential approval of these oral therapies could dramatically improve accessibility for patients. A key advantage of these oral agents in clinical trials is their apparent lack of association with amyloid-related imaging abnormalities (ARIA), a significant side effect of anti-Aβ mAbs that necessitates regular MRI monitoring. The absence of ARIA would further streamline treatment and reduce the need for intensive monitoring.
Supporting Data and Market Projections
The economic impact of these advancements is projected to be substantial. GlobalData forecasts that DMTs will constitute a dominant force in the global Alzheimer’s disease market, accounting for an estimated 63.7% of the market share by 2033. Within this segment, drugs targeting Aβ are expected to represent the majority. Specifically, Leqembi and Kisunla are projected to achieve global sales of approximately $2.8 billion and $2.9 billion, respectively, by 2033.
The growth trajectory is not solely reliant on the existing Aβ-targeting mAbs. Promising late-stage pipeline drugs with novel mechanisms of action are also poised to make a significant contribution. GlobalData highlights AriBio’s AR1001 (mirodenafil), Annovis Bio’s buntanetap, and Bristol Myers Squibb’s Cobenfy (xanomeline + trospium) as particularly promising oral drug candidates. AR1001 and buntanetap offer the convenience of once-daily oral dosing, facilitating seamless integration into clinical practice. Cobenfy, on the other hand, targets psychosis associated with Alzheimer’s disease, an area with no currently approved therapeutics, addressing a critical unmet need. If these drugs successfully navigate their ongoing Phase III trials, they are expected to broaden the therapeutic landscape beyond anti-Aβ mAbs and significantly contribute to market expansion.
Addressing Unmet Needs Beyond Treatment Access
Despite the anticipated robust growth and the advent of new therapies, significant unmet needs persist within the Alzheimer’s disease landscape. The rates of diagnosis and treatment initiation remain low across all disease stages, underscoring the urgent need for accurate, user-friendly diagnostic tests and reliable biomarkers for patient stratification and treatment response assessment.
While blood-based biomarkers are increasingly utilized in clinical trials and research, their transition into routine clinical practice is still evolving. A notable advancement occurred in May 2025 with the FDA’s clearance of Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio, the first blood test for diagnosing Alzheimer’s disease. This development signals a move towards more accessible and less invasive diagnostic methods.
Furthermore, the current DMTs, while offering a glimmer of hope, are considered moderately effective. There remains a substantial opportunity for the development of more potent DMTs that not only slow disease progression but potentially halt or even reverse it, with prevention being the ultimate goal. Beyond DMTs, there is a clear demand for therapies that can effectively improve cognition in the later stages of the disease. Additionally, more effective treatments for secondary symptoms such as agitation and psychosis are critical for improving the quality of life for individuals living with Alzheimer’s.
Key opinion leaders (KOLs) interviewed by GlobalData consistently emphasize that a single "cure" for Alzheimer’s disease is unlikely. Instead, they envision a future where treatment paradigms involve a multimodal approach, combining preventative strategies, symptomatic relief, and disease-modifying therapies. This integrated approach is seen as the most effective way to manage the complex and multifaceted nature of Alzheimer’s disease.
Implications for the Future of Alzheimer’s Care
The impending surge in the Alzheimer’s disease market signifies a period of unprecedented innovation and therapeutic advancement. The successful integration of DMTs, particularly those with more convenient administration routes like subcutaneous injections, will be crucial for maximizing patient benefit. The development of oral therapies not only promises greater accessibility but also potentially improved safety profiles by mitigating ARIA risks.
The focus on addressing secondary symptoms like psychosis and agitation, alongside the pursuit of more potent disease-modifying agents, highlights the industry’s commitment to a holistic approach to Alzheimer’s care. The increasing availability of accessible diagnostic tools, such as blood-based biomarkers, will empower earlier and more accurate diagnoses, enabling timely intervention and potentially improving treatment outcomes.
While the economic forecasts are undeniably optimistic, the challenges of affordability and equitable access will remain paramount. Continued dialogue between pharmaceutical companies, payers, and healthcare providers will be essential to ensure that these life-changing therapies reach the patients who need them most. The collaborative efforts to overcome these hurdles will not only drive market growth but, more importantly, offer renewed hope and improved quality of life for millions affected by this devastating disease. The Alzheimer’s disease market, though facing its share of complexities, is on a trajectory of significant expansion, driven by scientific breakthroughs and a growing understanding of the disease’s intricate pathology.
About the Author
